FDA approval of Bristol Myers Squibb’s Augtyro covers treatment of patients whose non-small cell lung cancer is driven by the rare ROS1 mutation. The molecule comes from BMS’s 2022 acquisition of Turning Point Therapeutics.
We need more research and consideration of other approaches to cancer treatment and development of new therapies that better account for the quality of life of cancer patients.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Antibody drug conjugates have made scientific and regulatory progress in recent years. Sanofi is partnering with ADC specialist Seagen in a multi-drug alliance that keeps the pharmaceutical giant in the mix of this growing field of cancer therapies.
A hot segment of targeted cancer therapy is using synthetic viruses, or pseudovirions, to serve as mini drug delivery capsules. These tiny protein shells are engineered to hone in to attack certain cancerous cells – avoiding healthy tissue completely. This model of treatment prevents the toxic cancers from affecting the non-cancerous parts of the body. Cambridge-based pseudovirion developer Aura […]